Biomarkers in Heart Disease
January 2009, Wiley-Blackwell
The book covers both the strengths and pitfalls of currently
available markers, and provides information on the most promising
biomarkers that are likely to impact practice in the next few
years. It is divided into four parts, organized around clinical
scenarios rather than individual biomarkers.
This book will help the practicing physician decide which biomarkers to measure, when to measure them, how to interpret the results and how to make decisions based on the test result.
1 Protocols for Diagnosing Myocardial Infarction.
2 Troponin and Other Markers of Necrosis for Risk Stratification in Patients with Acute Coronary Syndromes.
3 Challenges Interpreting Cardiac Troponin Values.
4 Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease.
5 Novel Markers in Patients with Suspected ACS.
Part II Biomarkers for Evaluation of Patients with Heart Failure.
6 Use of Natriuretic Peptides in the Diagnosis of Heart Failure.
7 Biomarkers for Risk Stratification in Patients with Heart Failure.
8 Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure.
Part III Biomarkers for Screening in the Ambulatory Populations.
10 Newer Markers for Population Screening.
Part IV A Look to the Future.
11 Moving Toward Personalized Medicine.
J. Fred Schoellkopf, Jr. Chair in Cardiology Research, Director, Coronary Care Unit and Cardiology Fellowship Program, UT Southwestern Medical Center, Dallas, TX, USA.
- Comprehensive but concise discussion of the role of biomarkers in heart disease
- Addresses use of biomarkers in current clinical practice, as
well as future indications for clinical practice
- Sections devoted to biomarkers in ischemic heart disease and
heart failure, as well as discussions of biomarkers in screening
and biomarkers in the future
- An essential read for anyone interested in the use of biomarkers in clinical practice